Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?
| Autor: | Ewa Cedrych, Ida Cedrych |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study business.industry medicine.medical_treatment Population medicine.disease Breast cancer Trastuzumab Internal medicine HER2 Positive Breast Cancer Neratinib medicine In patient skin and connective tissue diseases education Adverse effect business Adjuvant medicine.drug |
| Zdroj: | Oncology in Clinical Practice. 15:111-114 |
| ISSN: | 2450-6478 2450-1654 |
| DOI: | 10.5603/ocp.2019.0014 |
| Popis: | Neratinib is a new small molecule aimed at HER2 receptor. It has recently been approved in the United States of America and Europe for adjuvant treatment of patients with early, HER2-positive breast cancer, who underwent surgical resection followed by at least one year of adjuvant trastuzumab treatment. Despite initial enthusiasm, several factors limit the implementation of neratinib in clinical practice. These include: modest reduction of recurrence rate; limited data regarding the effect on overall survival; and a significant rate of adverse events. Thus, neratinib should be considered mainly in patients with high-risk HER2-positive breast cancer, because its clinical benefit might outweigh the side effects in this population. In the following article, we discuss the controversies regarding the pivotal phase III trial that eventually led to neratinib approval. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|